MedTrace Logo

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

NCT07259226 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-12-02

No results posted yet for this study

Summary

International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types.

Conditions

  • Advanced Breast Cancer
  • Advanced Gastric Cancer
  • Advanced Urothelial Cancer
  • Advanced Non Small Cell Lung Cancer (NSCLC)

Interventions

PROCEDURE

Biological samples collection

Biological samples collection (tumor tissue, blood, sputum) before initiation of treatment, during treatment, and at treatment discontinuation.

BEHAVIORAL

questionnaires to collect patient reported outcomes

QLQ-C30, QLQ-FA12, HADS, EQ-5D 5L

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Barbara Pistilli, MD, PhD · Gustave Roussy Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-14
Primary Completion
2030-11-01
Completion
2030-11-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07259226 on ClinicalTrials.gov